trending Market Intelligence /marketintelligence/en/news-insights/trending/fpeq68x9fjfd6qpjfzu-8w2 content esgSubNav
In This List

Endocyte announces changes to board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Endocyte announces changes to board

Endocyte Inc. said three of its directors will be stepping down at the company's 2018 annual meeting.

Each of Keith Brauer, Ann Hanham and Peter Meldrum are serving as class 2 directors of the company. Another class 2 director, Patrick Machado, will stand for re-election.

Meanwhile, the West Lafayette, Ind.-based biopharmaceutical company nominated Dawn Svoronos to serve on the company's board.

Svoronos has served as president of Merck & Co. Inc.'s Europe/Canada region. She is currently chair of the Theratechnologies Inc. board and is a director at Xenon Pharmaceuticals Inc., PTC Therapeutics Inc., and AgNovos Healthcare Co.

Endocyte, which develops treatments for cancer and inflammatory diseases, said Svoronos' experience will be valuable as it commercializes Lu-PSMA-617 to treat prostate cancer.